Literature DB >> 28703305

Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics.

Andrew Moore1, Anne Crossley2, Bernard Ng2, Lawrence Phillips3, Özgür Sancak2, K D Rainsford4.   

Abstract

OBJECTIVES: To test the ability of a multicriteria decision analysis (MCDA) model to incorporate disparate data sources of varying quality along with clinical judgement in a benefit-risk assessment of six well-known pain-relief drugs.
METHODS: Six over-the-counter (OTC) analgesics were evaluated against three favourable effects and eight unfavourable effects by seven experts who specialise in the relief of pain, two in a 2-day facilitated workshop whose input data and judgements were later peer-reviewed by five additional experts. KEY
FINDINGS: Ibuprofen salts and solubilised emerged with the best benefit-risk profile, followed by naproxen, ibuprofen acid, diclofenac, paracetamol and aspirin.
CONCLUSIONS: Multicriteria decision analysis enabled participants to evaluate the OTC analgesics against a range of favourable and unfavourable effects in a group setting that enabled all issues to be openly aired and debated. The model was easily communicated and understood by the peer reviewers, so the model should be comprehensible to physicians, pharmacists and other health professionals.
© 2017 Royal Pharmaceutical Society.

Entities:  

Keywords:  decision conferencing; group judgements; multicriteria decision analysis; over-the-counter analgesics; pain relief

Mesh:

Substances:

Year:  2017        PMID: 28703305     DOI: 10.1111/jphp.12770

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Multi-Criteria Decision Analysis to Develop an Efficacy-Safety Profile of Parenteral Analgesics Used in the Treatment of Postoperative Pain.

Authors:  Stephan Schug; Esther Pogatzki-Zahn; Lawrence D Phillips; Margaret Noyes Essex; Feng Xia; Alison J Reader; Robert Pawinski
Journal:  J Pain Res       Date:  2020-08-05       Impact factor: 3.133

2.  Medical cannabis in the UK: From principle to practice.

Authors:  Anne Katrin Schlag; David S Baldwin; Michael Barnes; Steve Bazire; Rachel Coathup; H Valerie Curran; Rupert McShane; Lawrence D Phillips; Ilina Singh; David J Nutt
Journal:  J Psychopharmacol       Date:  2020-06-10       Impact factor: 4.153

Review 3.  Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature.

Authors:  Marie-Laure Kürzinger; Ludivine Douarin; Ievgeniia Uzun; Chantal El-Haddad; William Hurst; Juhaeri Juhaeri; Stéphanie Tcherny-Lessenot
Journal:  Ther Adv Drug Saf       Date:  2020-12-08

4.  A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products.

Authors:  David J Nutt; Lawrence D Phillips; Michael P Barnes; Brigitta Brander; Helen Valerie Curran; Alan Fayaz; David P Finn; Tina Horsted; Julie Moltke; Chloe Sakal; Haggai Sharon; Saoirse E O'Sullivan; Tim Williams; Gregor Zorn; Anne K Schlag
Journal:  Cannabis Cannabinoid Res       Date:  2021-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.